Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7419981B2 · kind B2 · utility
14Cited by
5References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 3, 2004 |
| Grant date | Sep 2, 2008 |
| Priority date | — |
| Expiry date | May 22, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/53
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The instant invention relates to a combination of an alpha-2-delta ligand and a PDEV inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. A particularly preferred PDEV inhibitors is sildenafil.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.